Pfizer and Valneva announce that a phase 3 trial of the Lyme disease vaccine candidate PF-07307405 shows strong efficacy in adults and children.
Nivolumab plus AVD is now FDA-approved for previously untreated Stage III or IV classical Hodgkin lymphoma in patients aged 12 years and older.
Highest age-adjusted mortality rates seen for non-Hispanic Black women, followed by non-Hispanic Whites and Hispanics.
A long-debated plan to block teens from using tanning beds nationwide will not move forward. The US Food and Drug ...
No difference seen in intervention, control groups in composite of symptomatic stone recurrence, new stone formation, stone ...
Zilganersen is an investigational antisense oligonucleotide designed to reduce excess glial fibrillary acidic protein production in the central nervous system.
The melanocortin 4 receptor agonist setmelanotide is now FDA approved for weight management in adults and children with ...
Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...
Scientists are making rapid progress toward a long-awaited goal that could help to reshape cancer care: mRNA cancer vaccines ...
Previously, the Company had received CRLs in November 2023 and April 2025 due to insufficient evidence in addressing the ...
Keratoconus is a rare, progressive ophthalmic disorder characterized by changes to the cornea that result in significant ...
Enh3ance trial results indicate DTX301 reduces ammonia levels by 18% and supports dietary liberalization in patients with OTC deficiency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results